vs
Esperion Therapeutics, Inc.（ESPR）与GRID DYNAMICS HOLDINGS, INC.（GDYN）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是GRID DYNAMICS HOLDINGS, INC.的1.6倍（$168.4M vs $104.1M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 3.7%），过去两年GRID DYNAMICS HOLDINGS, INC.的营收复合增速更高（12.0% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Escape Dynamics Inc.是一家总部位于科罗拉多州的科技企业，活跃于2010年至2015年，核心业务方向是研发可单级入轨、依靠电磁驱动的可重复使用航天飞机，并推动该项目实现商业化落地。
ESPR vs GDYN — 直观对比
营收规模更大
ESPR
是对方的1.6倍
$104.1M
营收增速更快
ESPR
高出140.1%
3.7%
两年增速更快
GDYN
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $104.1M |
| 净利润 | — | $-1.5M |
| 毛利率 | — | 34.8% |
| 营业利润率 | 50.6% | 61.7% |
| 净利率 | — | -1.4% |
| 营收同比 | 143.7% | 3.7% |
| 净利润同比 | — | -150.6% |
| 每股收益（稀释后） | $0.32 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRGDYN
| Q1 26 | — | $104.1M | ||
| Q4 25 | $168.4M | $106.2M | ||
| Q3 25 | $87.3M | $104.2M | ||
| Q2 25 | $82.4M | $101.1M | ||
| Q1 25 | $65.0M | $100.4M | ||
| Q4 24 | $69.1M | $100.3M | ||
| Q3 24 | $51.6M | $87.4M | ||
| Q2 24 | $73.8M | $83.0M |
净利润ESPRGDYN
| Q1 26 | — | $-1.5M | ||
| Q4 25 | — | $306.0K | ||
| Q3 25 | $-31.3M | $1.2M | ||
| Q2 25 | $-12.7M | $5.3M | ||
| Q1 25 | $-40.5M | $2.9M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-29.5M | $4.3M | ||
| Q2 24 | $-61.9M | $-817.0K |
毛利率ESPRGDYN
| Q1 26 | — | 34.8% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 34.1% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 36.9% | ||
| Q3 24 | — | 37.4% | ||
| Q2 24 | — | 35.6% |
营业利润率ESPRGDYN
| Q1 26 | — | 61.7% | ||
| Q4 25 | 50.6% | 0.5% | ||
| Q3 25 | -11.4% | -0.2% | ||
| Q2 25 | 8.6% | -0.1% | ||
| Q1 25 | -34.0% | -2.0% | ||
| Q4 24 | -6.4% | 1.3% | ||
| Q3 24 | -31.0% | 2.4% | ||
| Q2 24 | 3.5% | 0.0% |
净利率ESPRGDYN
| Q1 26 | — | -1.4% | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | -35.9% | 1.1% | ||
| Q2 25 | -15.4% | 5.2% | ||
| Q1 25 | -62.2% | 2.9% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | -57.2% | 4.9% | ||
| Q2 24 | -83.9% | -1.0% |
每股收益（稀释后）ESPRGDYN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.32 | $0.01 | ||
| Q3 25 | $-0.16 | $0.01 | ||
| Q2 25 | $-0.06 | $0.06 | ||
| Q1 25 | $-0.21 | $0.03 | ||
| Q4 24 | $-0.14 | $0.06 | ||
| Q3 24 | $-0.15 | $0.05 | ||
| Q2 24 | $-0.33 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $327.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $530.1M |
| 总资产 | $465.9M | $605.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRGDYN
| Q1 26 | — | $327.5M | ||
| Q4 25 | $167.9M | $342.1M | ||
| Q3 25 | $92.4M | $338.6M | ||
| Q2 25 | $86.1M | $336.8M | ||
| Q1 25 | $114.6M | $325.5M | ||
| Q4 24 | $144.8M | $334.7M | ||
| Q3 24 | $144.7M | $231.3M | ||
| Q2 24 | $189.3M | $256.0M |
股东权益ESPRGDYN
| Q1 26 | — | $530.1M | ||
| Q4 25 | $-302.0M | $542.1M | ||
| Q3 25 | $-451.4M | $537.7M | ||
| Q2 25 | $-433.5M | $532.2M | ||
| Q1 25 | $-426.2M | $517.4M | ||
| Q4 24 | $-388.7M | $517.8M | ||
| Q3 24 | $-370.2M | $400.2M | ||
| Q2 24 | $-344.2M | $388.4M |
总资产ESPRGDYN
| Q1 26 | — | $605.0M | ||
| Q4 25 | $465.9M | $612.9M | ||
| Q3 25 | $364.0M | $613.2M | ||
| Q2 25 | $347.1M | $608.9M | ||
| Q1 25 | $324.0M | $590.9M | ||
| Q4 24 | $343.8M | $592.2M | ||
| Q3 24 | $314.1M | $477.3M | ||
| Q2 24 | $352.3M | $443.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRGDYN
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $9.9M | ||
| Q3 25 | $-4.3M | $7.0M | ||
| Q2 25 | $-31.4M | $14.4M | ||
| Q1 25 | $-22.6M | $9.4M | ||
| Q4 24 | $-35.0M | $7.1M | ||
| Q3 24 | $-35.3M | $9.2M | ||
| Q2 24 | $-7.2M | $10.7M |
自由现金流ESPRGDYN
| Q1 26 | — | — | ||
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $-35.5M | $5.9M | ||
| Q2 24 | $-7.3M | $8.0M |
自由现金流率ESPRGDYN
| Q1 26 | — | — | ||
| Q4 25 | — | 5.7% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | -68.7% | 6.8% | ||
| Q2 24 | -9.9% | 9.7% |
资本支出强度ESPRGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 4.1% | ||
| Q1 25 | 0.0% | 3.3% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 0.3% | 3.7% | ||
| Q2 24 | 0.1% | 3.2% |
现金转化率ESPRGDYN
| Q1 26 | — | — | ||
| Q4 25 | — | 32.34× | ||
| Q3 25 | — | 5.92× | ||
| Q2 25 | — | 2.73× | ||
| Q1 25 | — | 3.21× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GDYN
暂无分部数据
